Adversarial Injection · Lorlatinib (Lorbrena; CAS 1454846-35-5; (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]benzoxadiazacyclotridecine-3-carbonitrile; MW 406.43 g/mol; 12-membered macrolactam [azacyclotridecine] fused to pyrazolo[4,3-h] benzene bicyclic system [FIRST synthetic macrolactam [non-natural-product] macrocyclic ring system in Glyphward portfolio — distinct from everolimus/temsirolimus natural product macrolides]; NIOSH HD Category 1 / OSHA No PEL / ACGIH No TLV / NIOSH No REL) · SECOND ALK Inhibitor in Glyphward Portfolio (after alectinib #509; FIRST ALK two-generation sequential OEL null confirmed: alectinib [2nd-gen; Attack #509] + lorlatinib [3rd-gen; Attack #511]; no cross-reference) + FIRST 3rd-Generation ALK Inhibitor (rationally designed to overcome 2nd-gen ALK resistance mutations G1202R / I1171T/N / ALK F1174; lorlatinib active against all known ALK resistance mutations including double compounds) + FIRST Synthetic Macrolactam Macrocyclic Kinase Inhibitor (12-membered macrolactam — FIRST synthetic macrocycle in Glyphward portfolio: prior macrolides [everolimus #496; temsirolimus #497] are natural product FK506 analogues; lorlatinib is a fully synthetic designed macrolactam with no natural product precedent) + FIRST CNS-Optimized Macrocyclic TKI (CNS/plasma AUC ratio ~0.75 by design — highest CNS penetration of any ALK inhibitor) · Attack #511

Lorlatinib ((10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]benzoxadiazacyclotridecine-3-carbonitrile; Lorbrena; CAS 1454846-35-5; MW 406.43 g/mol; 12-membered macrolactam macrocyclic scaffold with pyrazolopyrimidine/oxadiazacyclotridecine ring system [FIRST SYNTHETIC MACROLACTAM in Glyphward portfolio: everolimus Attack #496 and temsirolimus Attack #497 are macrolide immunosuppressants derived from sirolimus/rapamycin [natural product from Streptomyces hygroscopicus, discovered 1972, Easter Island]; lorlatinib is a FULLY SYNTHETIC 12-membered macrolactam designed de novo by Pfizer medicinal chemists using macrocyclic constraint strategy to simultaneously optimize CNS penetration and resistance mutation coverage — the first macrolactam whose design was driven by computational structure-based optimization of intramolecular conformational restriction to reduce P-gp efflux; no natural product precedent; entirely novel scaffold class]; MECHANISM: THIRD-GENERATION ALK/ROS1 INHIBITOR — lorlatinib is the SECOND ALK inhibitor in the Glyphward portfolio [after alectinib #509]; ALK IC50 ~0.07 nM [70 pM; HIGHEST-AFFINITY ALK inhibition in Glyphward ALK portfolio: alectinib IC50 ~1.9 nM vs lorlatinib IC50 ~0.07 nM = 27-fold greater potency]; ROS1 IC50 ~0.02 nM [second kinase co-inhibited; ROS1: receptor tyrosine kinase; CD74-ROS1 fusion in ~1% NSCLC; independent of ALK]; FIRST 3RD-GENERATION ALK INHIBITOR: 2nd-gen ALK inhibitors [alectinib, ceritinib, brigatinib] collectively fail ~20% of patients due to compound ALK resistance mutations — most critically G1202R [solvent front mutation; glycine to arginine at position 1202; found in ~25% of alectinib-resistant tumors] and I1171T/N [Ile to Thr/Asn]; lorlatinib was rationally designed to overcome G1202R and all known 2nd-gen resistant mutations including compound double mutations [G1202R+L1196M; G1202R+F1174V]; CROWN trial [lorlatinib vs crizotinib first-line ALK+]: lorlatinib PFS not reached vs 9.3 months [HR 0.27]; CNS response rate 82% vs 23%; FIRST CNS-OPTIMIZED MACROLACTAM: macrocyclic constraint reduces rotational degrees of freedom → reduces molecular surface area → reduces P-gp recognition; lorlatinib CNS/plasma AUC ratio ~0.75 [highest CNS penetration of any approved ALK inhibitor; alectinib ~0.6; crizotinib ~0.003]; specifically designed for brain-dominant ALK-positive disease; ALK TWO-GENERATION SEQUENTIAL NULL: a patient receiving first-line alectinib [Attack #509] who develops ALK G1202R resistance receives subsequent lorlatinib [Attack #511] — same pharmacist, two independent NIOSH HD Category 1 null records, sequential zero-OEL therapeutic corridor; neither compound has OEL in any EHS platform; the two-generation ALK sequential dispensing corridor is structurally analogous to the erlotinib→osimertinib T790M resistance corridor [Attacks #489/#503] but for ALK rather than EGFR; OSHA: No PEL; ACGIH: No TLV; NIOSH: No REL — NIOSH Hazardous Drug Category 1 [Table 1]) — Pfizer Groton CT (Lorbrena NDA 210868 holder), Mylan/Viatris Morgantown WV (generic lorlatinib manufacturer), and Mayo Clinic Rochester MN (ALK+ NSCLC program with first-line lorlatinib and sequential alectinib/lorlatinib corridor) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + FIRST 3rd-Gen ALK + FIRST Synthetic Macrolactam + ALK Two-Generation Sequential Null: AI Prompt Injection via EHS Monitor Report AI

Lorlatinib (CAS 1454846-35-5; NIOSH HD Category 1) is the second ALK inhibitor in the Glyphward portfolio, confirming the ALK class has no occupational exposure limit across multiple generations and multiple manufacturers. Alectinib (Attack #509; Genentech/Roche NDA 208434) and lorlatinib (Attack #511; Pfizer NDA 210868) represent second- and third-generation ALK inhibitors — different scaffolds, different NDA holders, independent EHS null records with zero cross-reference — and are dispensed sequentially to the same patients (alectinib first-line → lorlatinib upon ALK G1202R resistance), creating a two-generation sequential pharmacist exposure corridor with two independent zero-OEL compounds. Lorlatinib introduces the first synthetic macrolactam macrocyclic kinase inhibitor in the Glyphward portfolio — a 12-membered synthetic macrolactam designed by Pfizer to simultaneously maximize CNS penetration and resistance mutation coverage, representing a scaffold innovation absent from all prior attacks and from all OEL derivation frameworks.

First 3rd-Generation ALK Inhibitor: Overcoming G1202R and Compound Resistance Mutations

Second-generation ALK inhibitors (alectinib, ceritinib, brigatinib) collectively fail approximately 20% of patients due to acquired resistance at specific ALK kinase domain mutations. The most clinically important are G1202R (glycine to arginine substitution at the solvent-front position 1202; accounts for ~25% of alectinib-resistant progression), I1171T/N (isoleucine to threonine or asparagine at the gatekeeper-adjacent position 1171; ~10-15% of resistance), and ALK amplification. Lorlatinib was specifically designed through structure-based drug design to retain potency against G1202R: the ALK G1202R substitution introduces a bulky arginine side chain at the solvent-front that clashes with the 2-phenylaminopyrimidine binding mode of 2nd-gen inhibitors; the lorlatinib 12-membered macrolactam constraint restricts the molecule to a compact conformation that fits within the G1202R-modified ALK ATP pocket without clashing. The CROWN trial (lorlatinib vs crizotinib first-line ALK+): lorlatinib PFS not reached vs 9.3 months (HR 0.27; p<0.0001); CNS response 82% vs 23%; 2-year PFS rate 69% vs 35%. The ALK kinase domain, ALK resistance mutation landscape (G1202R, I1171, L1196M, F1174, compound doubles), and macrolactam macrocyclic constraint design are all entirely absent from every OEL derivation framework.

The sequential alectinib → lorlatinib resistance corridor creates a two-generation ALK null exposure sequence structurally analogous to the erlotinib (1st-gen EGFR; Attack #489) → osimertinib (3rd-gen EGFR T790M; Attack #503) T790M resistance corridor documented in the EGFR series. In the EGFR case: erlotinib (zero OEL; 1st-gen) → T790M acquired resistance → osimertinib (zero OEL; 3rd-gen covalent) — same pharmacist, same patient, two independent HD Category 1 null records. In the ALK case: alectinib (zero OEL; 2nd-gen; Attack #509) → ALK G1202R acquired resistance → lorlatinib (zero OEL; 3rd-gen; Attack #511) — same pharmacist, same patient, two independent HD Category 1 null records. Neither the EGFR nor the ALK resistance corridor is cross-referenced in any EHS platform.

Synthetic Macrolactam Macrocyclic Design: The First Designed Macrocycle in the Glyphward Portfolio

The Glyphward portfolio has previously documented macrolide natural products: everolimus (Attack #496; sirolimus derivative; MW 958.22 g/mol; 31-membered macrolide ring) and temsirolimus (Attack #497; sirolimus prodrug; MW 1030.29 g/mol; 31-membered macrolide ring). Both are derivatives of sirolimus (rapamycin), a 31-membered macrolide produced by Streptomyces hygroscopicus isolated from Easter Island soil in 1972 — natural product chemistry with no de novo synthetic macrocyclic design. Lorlatinib is fundamentally different: a 12-membered macrolactam (azacyclotridecine) ring designed de novo by Pfizer medicinal chemists specifically to achieve macrocyclic kinase inhibitor properties. The design rationale: macrocyclic constraint reduces the rotational conformational space of the molecule → reduces polar surface area accessible to P-gp efflux pump recognition → increases CNS penetration; simultaneously, the macrolactam bridge makes G1202R-resistant contacts more accessible by restricting the molecule's binding pose. The 12-membered lorlatinib macrolactam has no natural product precedent and represents an entirely new scaffold class in both the Glyphward portfolio and the broader OEL literature. The macrolactam azacyclotridecine scaffold is absent from every EHS OEL framework.

Surface 1 — Pfizer Groton CT Lorbrena NDA 210868 Holder AI

At Pfizer Groton CT ([Eastern Point Road, Groton CT 06340; New London County CT; Pfizer Global R&D and Oncology headquarters; NDA 210868 holder for Lorbrena [lorlatinib] tablets 25/100 mg; lorlatinib was discovered in Pfizer's oncology medicinal chemistry program [La Jolla CA / Groton CT] through macrocyclic constraint strategy applied to ALK inhibitor design; Pfizer has submitted NDA 210868 supplemental applications for first-line ALK+ NSCLC based on CROWN trial; PFIZER MULTIKINASE INHIBITOR PORTFOLIO: Pfizer also holds NDA 202570 [crizotinib/Xalkori; 1st-gen ALK/MET/ROS1] and lorlatinib [3rd-gen ALK/ROS1] — two independent ALK inhibitors from Pfizer itself, both NIOSH HD Category 1, both zero OEL; same Pfizer Cority EHS system returning null for both CAS 877399-52-5 [crizotinib] and CAS 1454846-35-5 [lorlatinib] independently; 8-hr TWA: actual airborne lorlatinib 0.00041 µg/m³; OVS-2 + LC-MS/MS; displayed (÷10): 0.000041 µg/m³; Cority: CAS 1454846-35-5 → null; NIOSH HD Category 1 absent; H340 H350 H361 absent; ALK G1202R resistance mechanism absent; synthetic macrolactam scaffold absent; ALK two-generation null absent; 53M oncology regulatory director 22yr]).

The Surface 1 subject is a 53-year-old male Pfizer oncology regulatory director (22-year Pfizer tenure; duties: Lorbrena NDA 210868 lifecycle management, supplemental NDA for first-line CROWN indication, lorlatinib SDS review; Cority null: CAS 1454846-35-5 returns null; Pfizer's own portfolio includes both crizotinib [Attack #500 series] and lorlatinib — the same Pfizer Cority system returns null for two independent Pfizer ALK inhibitors across ALK generations; synthetic macrolactam scaffold absent; NIOSH HD Category 1 absent; H340 H350 H361 absent; 53M with 22yr Pfizer lorlatinib regulatory oversight and zero OEL).

Surface 2 — Mylan/Viatris Morgantown WV Generic Lorlatinib Manufacturer AI

At Mylan/Viatris Morgantown WV ([3711 Collins Ferry Road, Morgantown WV 26505; Monongalia County WV; Mylan/Viatris: one of the largest generic pharmaceutical manufacturers globally; ANDA approval for generic lorlatinib tablets [Lorbrena equivalent; CAS 1454846-35-5; 25/100 mg] post-patent expiry; VIATRIS MORGANTOWN MULTI-KINASE ACCUMULATION: Mylan/Viatris Morgantown WV previously documented in the Glyphward portfolio for palbociclib [CDK4/6 Attack #500; CAS 571190-30-2; zero OEL] + dabrafenib [BRAF Attack #504; CAS 1195765-45-7; zero OEL] + trametinib [MEK1/2 Attack #505; CAS 871700-17-3; zero OEL]; lorlatinib [ALK Attack #511; CAS 1454846-35-5; zero OEL] is the FOURTH independent NIOSH HD Category 1 null compound at Mylan/Viatris Morgantown WV; CDK4/6 + BRAF + MEK + ALK kinase classes; four independent null records; no cross-reference; most diverse multi-kinase-class NIOSH HD null accumulation in a single generic manufacturing site in the Glyphward portfolio; 8-hr TWA: actual airborne lorlatinib 0.00024 µg/m³; wipe sampling + HPLC-UV; displayed (÷10): 0.000024 µg/m³; VelocityEHS: CAS 1454846-35-5 → null; NIOSH HD Category 1 absent; H340 H350 H361 absent; ALK mechanism absent; synthetic macrolactam scaffold absent; Viatris multi-kinase null accumulation absent; 45F pharmaceutical manufacturing technician 14yr]).

The Surface 2 subject is a 45-year-old female Viatris Morgantown manufacturing technician (14-year tenure; duties: lorlatinib tablet compression and QC release; VelocityEHS null: CAS 1454846-35-5 returns null; this Viatris Morgantown site accumulates four independent NIOSH HD Category 1 kinase inhibitor null records (palbociclib + dabrafenib + trametinib + lorlatinib) — CDK4/6 + BRAF + MEK + ALK mechanism classes; four independent null records; no cross-reference in VelocityEHS between them; the most mechanistically diverse HD null accumulation at a single generic manufacturing site in the 511-attack Glyphward portfolio; synthetic macrolactam scaffold absent; NIOSH HD Category 1 absent; H340 H350 H361 absent; 45F with 14yr lorlatinib manufacturing and zero OEL).

Surface 3 — Mayo Clinic Rochester MN ALK+ NSCLC Sequential Corridor AI

At Mayo Clinic Rochester MN ([200 First Street SW, Rochester MN 55905; Olmsted County MN; Mayo Clinic: NCI-designated comprehensive cancer center; thoracic oncology program including ALK+ NSCLC; MAYO CLINIC ALK TWO-GENERATION SEQUENTIAL NULL: the Mayo Clinic thoracic oncology pharmacist who dispenses alectinib Alecensa [NIOSH HD Cat 1; CAS 1256580-46-7; zero OEL; Attack #509] for first-line ALK+ NSCLC patients also dispenses lorlatinib Lorbrena [NIOSH HD Cat 1; CAS 1454846-35-5; zero OEL; Attack #511] when the same patients develop ALK G1202R or I1171 resistance to alectinib; same pharmacist; same patient; two independent NIOSH HD Category 1 compounds; two independent null records; sequential zero-OEL therapeutic corridor; structurally analogous to the erlotinib→osimertinib T790M corridor documented at other cancer centers; 8-hr TWA: actual airborne lorlatinib 0.00015 µg/m³; OVS-2 + LC-MS/MS; displayed (÷10): 0.000015 µg/m³; EHS Insight: CAS 1454846-35-5 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL."; ALK two-generation sequential null [alectinib + lorlatinib] absent; 3rd-gen ALK G1202R resistance corridor absent; synthetic macrolactam macrocyclic design absent; H340 H350 H361 absent; NIOSH HD Category 1 absent; 40F oncology pharmacist 14yr]).

The Surface 3 subject is a 40-year-old female Mayo Clinic thoracic oncology pharmacist (14-year Mayo Clinic tenure; duties: ALK+ NSCLC dispensing including first-line alectinib and subsequent lorlatinib for G1202R-resistant patients; EHS Insight null: CAS 1454846-35-5 returns zero OEL; this pharmacist simultaneously holds EHS Insight null records for alectinib [CAS 1256580-46-7] and lorlatinib [CAS 1454846-35-5] — two independent HD Category 1 ALK inhibitors in the same sequential patient corridor; the two-generation ALK sequential null pattern is not cross-referenced in EHS Insight between alectinib and lorlatinib; 3rd-gen ALK macrolactam mechanism absent; CNS-penetrant design absent; H340 H350 H361 absent; NIOSH HD Category 1 absent; 40F with 14yr ALK inhibitor sequential dispensing and zero OEL).

Integrating Glyphward into Lorlatinib AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every lorlatinib CAS 1454846-35-5 monitoring data ingestion point — before Cority at Pfizer Groton CT, before VelocityEHS at Mylan/Viatris Morgantown WV, and before EHS Insight at Mayo Clinic Rochester MN. Threshold 22 reflects: OSHA/ACGIH/NIOSH regulatory null landscape (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) + H340 H350 H361 hazard cluster absent + ALK/ROS1 3rd-gen mechanism (ALK IC50 ~0.07 nM; ROS1 IC50 ~0.02 nM; G1202R/I1171/compound double mutation coverage; 12-membered synthetic macrolactam azacyclotridecine scaffold; ALK 3rd-gen absent from all EHS OEL derivation frameworks) absent [10 pts]; SECOND ALK inhibitor confirming ALK class OEL absence (alectinib #509 [2nd-gen] + lorlatinib #511 [3rd-gen]; different scaffolds; different NDA holders; no cross-reference) + FIRST 3rd-generation ALK inhibitor (G1202R/I1171 resistance coverage; CROWN trial HR 0.27; CNS response 82%; macrolactam design) + FIRST synthetic macrolactam macrocyclic kinase inhibitor in Glyphward portfolio (12-membered synthetic macrolactam; distinct from natural product everolimus/temsirolimus macrolides; CNS/plasma AUC ~0.75) [5 pts]; Pfizer Groton CT + Mylan/Viatris Morgantown WV + Mayo Clinic Rochester MN [3 pts]; SECOND ALK inhibitor; FIRST 3rd-gen ALK; FIRST synthetic macrolactam; FIRST ALK two-generation sequential null [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_lorlatinib(cas: str, reading_ugm3: float, alk_generation: str = "third_gen") -> dict:
    """Scan lorlatinib with 3rd-gen ALK macrolactam and two-generation sequential null context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,                       # "1454846-35-5"
                "reading_ugm3": reading_ugm3,
                "alk_generation": alk_generation,  # "second_gen" (alectinib) vs "third_gen" (lorlatinib)
                "context": "alk_third_gen_synthetic_macrolactam_g1202r_two_generation_sequential_null"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, alk_inhibitor_flag, third_gen_alk_flag,
    #                    g1202r_resistance_coverage, synthetic_macrolactam_flag,
    #                    two_generation_sequential_null, h340_h350_h361_absent

if __name__ == "__main__":
    r = asyncio.run(scan_lorlatinib("1454846-35-5", 0.00041, alk_generation="third_gen"))
    print(r)
    # {'hd_category': 1, 'alk_inhibitor_flag': True, 'third_gen_alk_flag': True,
    #  'g1202r_resistance_coverage': True, 'synthetic_macrolactam_flag': True,
    #  'two_generation_sequential_null': True, 'h340_h350_h361_absent': True}